Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms

Blood Adv (2021) 5 (19): 3776–3788.

https://doi.org/10.1182/bloodadvances.2020003597

Published: 2021

Includes: Supplemental data

Journal Articles

Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis

Derek C. H. Chan, Joshua Xu, Ana Vujovic, Nicholas Wong, Victor Gordon, Laura P. M. H. de Rooij, Steven Moreira, Cailin E. Joyce, Jose La Rose, María-José Sandí, Bradley W. Doble, Carl D. Novina, Robert K. Rottapel, Kristin J. Hope

Blood Adv (2021) 5 (16): 3120–3133.

https://doi.org/10.1182/bloodadvances.2020002539

Published: 2021

Includes: Supplemental data

Journal Articles

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Ingrid Spaan, Laura M. Timmerman, Thomas Kimman, Anne Slomp, Marta Cuenca, Niels van Nieuwenhuijzen, Laura M. Moesbergen, Monique C. Minnema, Reinier A. Raymakers, Victor Peperzak

Blood Adv (2021) 5 (12): 2593–2607.

https://doi.org/10.1182/bloodadvances.2020003624

Published: 2021

Includes: Supplemental data

Journal Articles

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, Elke De Bruyne

Blood Adv (2021) 5 (9): 2325–2338.

https://doi.org/10.1182/bloodadvances.2020003217

Published: 2021

Includes: Supplemental data

Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis

Blood Adv (2021) 5 (8): 2165–2172.

https://doi.org/10.1182/bloodadvances.2020003731

Published: 2021

Includes: Supplemental data

Journal Articles

Adenylate kinase 2 expression and addiction in T-ALL

Nabih Maslah, Mehdi Latiri, Vahid Asnafi, Mélanie Féroul, Nawel Bedjaoui, Thomas Steimlé, Emmanuelle Six, Els Verhoyen, Elizabeth Macintyre, Chantal Lagresle-Peyrou, Ludovic Lhermitte, Guillaume P. Andrieu

Blood Adv (2021) 5 (3): 700–710.

https://doi.org/10.1182/bloodadvances.2020002700

Published: 2021

Includes: Supplemental data

Journal Articles

Thioridazine requires calcium influx to induce MLL-AF6 –rearranged AML cell death

Claudia Tregnago, Ambra Da Ros, Elena Porcù, Maddalena Benetton, Manuela Simonato, Luca Simula, Giulia Borella, Katia Polato, Sonia Minuzzo, Giulia Borile, Paola Cogo, Silvia Campello, Alessandro Massi, Romeo Romagnoli, Barbara Buldini, Franco Locatelli, Martina Pigazzi

Blood Adv (2020) 4 (18): 4417–4429.

https://doi.org/10.1182/bloodadvances.2020002001

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Exploitable metabolic dependencies in MLL-ENL–induced leukemia

Maria-Paz Garcia-Cuellar, Jennifer Lawlor, Martin Böttcher, Dimitrios Mougiakakos, Markus Metzler, Robert K. Slany

Blood Adv (2020) 4 (15): 3626–3638.

https://doi.org/10.1182/bloodadvances.2020001710

Published: 2020

Includes: Supplemental data

Journal Articles

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Thomas E. C. Cummin, Kerry L. Cox, Tom D. Murray, Anna H. Turaj, Lisa Dunning, Vikki L. English, Rachel Fell, Graham Packham, Yan Ma, Ben Powell, Peter W. M. Johnson, Mark S. Cragg, Matthew J. Carter

Blood Adv (2020) 4 (14): 3316–3328.

https://doi.org/10.1182/bloodadvances.2020002231

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes

Blood Adv (2020) 4 (9): 2032–2043.

https://doi.org/10.1182/bloodadvances.2019000757

Published: 2020

Includes: Supplemental data

Journal Articles

Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1–infected cells

Emi Ikebe, Sahoko Matsuoka, Kenta Tezuka, Madoka Kuramitsu, Kazu Okuma, Makoto Nakashima, Seiichiro Kobayashi, Junya Makiyama, Makoto Yamagishi, Seiichi Oyadomari, Kaoru Uchimaru, Isao Hamaguchi

Blood Adv (2020) 4 (9): 1845–1858.

https://doi.org/10.1182/bloodadvances.2019001139

Published: 2020

Includes: Supplemental data

Journal Articles

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D. J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David C. Taussig, Spiros Linardopoulos

Blood Adv (2020) 4 (7): 1478–1491.

https://doi.org/10.1182/bloodadvances.2019000986

Published: 2020

Includes: Supplemental data

Journal Articles

Germline heterozygous mutations in Nxf1 perturb RNA metabolism and trigger thrombocytopenia and lymphopenia in mice

Stéphane Chappaz, Charity W. Law, Mark R. Dowling, Kirstyn T. Carey, Rachael M. Lane, Linh H. Ngo, Vihandha O. Wickramasinghe, Gordon K. Smyth, Matthew E. Ritchie, Benjamin T. Kile

Blood Adv (2020) 4 (7): 1270–1283.

https://doi.org/10.1182/bloodadvances.2019001323

Published: 2020

Includes: Supplemental data

Journal Articles

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Anne Slomp, Laura M. Moesbergen, Jia-nan Gong, Marta Cuenca, Peter A. von dem Borne, Pieter Sonneveld, David C. S. Huang, Monique C. Minnema, Victor Peperzak

Blood Adv (2019) 3 (24): 4202–4214.

https://doi.org/10.1182/bloodadvances.2019000702

Published: 2019

Includes: Supplemental data

Journal Articles

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC

Stacy Grieve, Gabriel Wajnberg, Miranda Lees, Simi Chacko, Jackson Weir, Nicolas Crapoulet, Tony Reiman

Blood Adv (2019) 3 (22): 3613–3625.

https://doi.org/10.1182/bloodadvances.2019000374

Published: 2019

Includes: Supplemental data

Journal Articles

Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil

F. Fioredda, E. Cappelli, A. Mariani, A. Beccaria, E. Palmisani, A. Grossi, I. Ceccherini, R. Venè, C. Micalizzi, M. Calvillo, F. Pierri, I. Mancini, F. Peyvandi, F. Corsolini, C. Dufour, M. Miano

Blood Adv (2019) 3 (21): 3432–3435.

https://doi.org/10.1182/bloodadvances.2019000575

Published: 2019

Journal Articles

Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion

Tomohiro Umezu, Satoshi Imanishi, Seiichiro Yoshizawa, Chiaki Kawana, Junko H. Ohyashiki, Kazuma Ohyashiki

Blood Adv (2019) 3 (21): 3228–3240.

https://doi.org/10.1182/bloodadvances.2019000403

Published: 2019

Includes: Supplemental data

Journal Articles

Acute myeloid leukemia–induced T-cell suppression can be reversed by inhibition of the MAPK pathway

Kaycee B. Moshofsky, Hyun J. Cho, Guanming Wu, Kyle A. Romine, Matthew T. Newman, Yoko Kosaka, Shannon K. McWeeney, Evan F. Lind

Blood Adv (2019) 3 (20): 3038–3051.

https://doi.org/10.1182/bloodadvances.2019000574

Published: 2019

Journal Articles

In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis

Yanyan Zhang, Ghaith Wedeh, Liang He, Monika Wittner, Florian Beghi, Viviane Baral, Jean-Marie Launay, Siham Bibi, Fernando Doñate, Hosein Kouros-Mehr, Michel Arock, Fawzia Louache

Blood Adv (2019) 3 (4): 633–643.

https://doi.org/10.1182/bloodadvances.2018026179

Published: 2019

Includes: Supplemental data

Journal Articles

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia

Blood Adv (2019) 3 (3): 242–255.

https://doi.org/10.1182/bloodadvances.2018024182

Published: 2019

Includes: Supplemental data

NARROW

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms

Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Adenylate kinase 2 expression and addiction in T-ALL

Thioridazine requires calcium influx to induce MLL-AF6 –rearranged AML cell death

Exploitable metabolic dependencies in MLL-ENL–induced leukemia

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1–infected cells

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Germline heterozygous mutations in Nxf1 perturb RNA metabolism and trigger thrombocytopenia and lymphopenia in mice

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC

Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil

Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion

Acute myeloid leukemia–induced T-cell suppression can be reversed by inhibition of the MAPK pathway

In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only